GlassScriptPhysician profile
Badi Altawil
NPI 1841281797
$14,044.44
in general payments reported to CMS, 2019-2025
37 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,852 · 2020: $1,415 · 2021: $2,284 · 2022: $2,622 · 2023: $3,324 · 2024: $927 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,871.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,805.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,497.61 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $1,484.02 | 2019-2023 | |
| Abbvie INC. | $1,335.87 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,227.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $915.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $805.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $766.94 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $716.70 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $476.26 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $352.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $334.13 | 2021-2025 | Rexulti, Abilify Maintena |
| Kowa Pharmaceuticals America, INC. | $269.13 | 2019-2021 | |
| Pfizer INC. | $264.38 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $257.63 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Badi Altawil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.